Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PrefGel (Straumann PrefGel) is a topical dental conditioning agent consisting of a 24% concentration of edetic acid (EDTA) formulated in a neutral pH gel. Developed and manufactured by Straumann, it is primarily utilized during periodontal and peri-implant surgical procedures to decontaminate and condition root and implant surfaces. As a chelating agent, PrefGel binds to calcium ions to effectively remove the smear layer and expose the collagenous matrix of the dentin or clean the titanium surface of dental implants. This surface conditioning facilitates the subsequent adsorption of regenerative materials, such as enamel matrix derivatives (e.g., Emdogain), to promote tissue attachment and regeneration. PrefGel is clinically indicated for the surgical management of peri-implantitis and chronic periodontitis to improve regenerative outcomes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on edetic acid.